Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05226078 · ClinicalTrials.gov registry record · NA
The Association Between CBT-I Dose, Sleep Duration, and Fatigue in Breast Cancer Patients
A NA study of Chronic Insomnia and Cancer-related Problem/Condition, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- NA
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT05226078: Active NA study of Chronic Insomnia and Cancer-related Problem/Condition, sponsored by Abramson Cancer Center at Penn Medicine.
NCT05226078 is a NA study of Chronic Insomnia and Cancer-related Problem/Condition that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 64 participants, below the 25,393-participant average among 11 other Chronic Insomnia trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05226078, a NA study of Chronic Insomnia and Cancer-related Problem/Condition, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
Cancer-related fatigue (CRF) and insomnia are prevalent among cancer patients and have been linked to de-creases in quality of life and poorer overall survivorship. Currently, the mechanisms underlying CRF are not well understood, which has led to treatments that are only moderately effective. In addition, when compared to CBT-I in the general population, the treatment outcomes in CBT-I with cancer patients are subpar and, as such, this study will evaluate whether dose of CBT-I is effective in ameliorating CRF.
Primary Outcome
Proportion of screened eligible subjects who: complete a screener; enroll; and accept randomization.
Conditions Studied
Interventions
- BEHAVIORAL Cognitive Behavioral Therapy for Insomnia
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2026-11-30 |
| Phase | NA |
What the registry record for NCT05226078 still lists
NCT05226078 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 25,393-participant average among 11 other Chronic Insomnia trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Chronic Insomnia appearing as the primary indexed condition, and to 1 intervention - of which Cognitive Behavioral Therapy for Insomnia is the first listed.
NCT05226078 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05226078 about?
NCT05226078 is a clinical study titled "The Association Between CBT-I Dose, Sleep Duration, and Fatigue in Breast Cancer Patients". Cancer-related fatigue (CRF) and insomnia are prevalent among cancer patients and have been linked to de-creases in quality of life and poorer overall survivorship. Currently, the mechanisms underlying CRF are not well understood, which has led to treatments that are only moderately effective. In ad...
What is the current status of trial NCT05226078?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 64 participants. The study started on 2023-03-01. Estimated completion is 2026-11-30.
What conditions does trial NCT05226078 study?
This clinical trial studies the following conditions: Chronic Insomnia, Cancer-related Problem/Condition, Cancer-Related Syndrome.
What interventions are being tested in trial NCT05226078?
The interventions under investigation include: Cognitive Behavioral Therapy for Insomnia (BEHAVIORAL).
Who is sponsoring clinical trial NCT05226078?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05226078 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05226078's enrollment target sits among peer trials
64 9th of 11 higher than 3 of 11 other Chronic Insomnia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Insomnia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Sleep and Reducing Opioid Use in Individuals With Chronic Pain
RECRUITING · NA
-
Insomnia Behavioral Intervention Study
RECRUITING · NA
-
Comparing Insomnia Care As Usual to Digital Augmentation (CICADA)
RECRUITING · NA
-
Sleep and Pain Intervention for Chronic Widespread Pain Pilot Study
COMPLETED · NA
-
Naturalistic Monitoring and Treatment of Chronic Insomnia
COMPLETED · NA
-
Brief Behavioral Treatment for Insomnia in Cancer Survivors
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI